DNB // Back Bay
Strategic and Financing Partner to Global Healthcare

AdobeStock_275264961.jpeg
 

A unique integrated strategy and corporate and investment banking solution for global and emerging life science and healthcare companies.

The DNB//Back Bay Healthcare Partnership provides essential strategic and financial support to healthcare companies. We have a unique position bridging the Nordic and U.S. markets. Together, we provide a 360-degree understanding of healthcare corporate development, from chemistry to commercialization and raising capital to M&A as companies move through their lifecycle.

ABOUT THE PARTNERSHIP

The DNB//Back Bay Partnership was formalized in 2023 to provide healthcare companies with strategic guidance, M&A and partnering support and execution and capabilities in global capital markets and investment and commercial banking.

DNB, headquartered in Oslo, Norway, and Back Bay Life Science Advisors, headquartered in Boston, Massachusetts, are recognized leaders in banking and global life science development. Together, DNB and Back Bay Life Science Advisors offer unique support to companies along the full continuum of life science and healthcare development.

The DNB // Back Bay Partnership is comprised of dedicated multidisciplinary teams of healthcare experts and corporate and investment bankers who understand the complete picture of asset and company development.


Our combined expertise in healthcare and banking spans more than 110 years and 1,000 successful projects and transactions.

Learn more about the Partnership, subscribe for market insights, request an overview of our capabilities or connect with our advisors.

 

Nordic-American Healthcare Conference 2025

The Leading US-Nordic Healthcare Public Equity Investor Conference Will Take Place March 26-27, 2025 in New York City.

Dates have been announced for the 9th annual NAHC. Hosted by DNB//Back Bay with Nasdaq Nordic, Innovation Norway and Business Sweden, this pre-eminent US-based Nordic healthcare equity investor event will convene in New York City on March 26–27, 2025, bringing together industry leaders, investors and innovators from across the global healthcare sector. LEARN MORE AND REQUEST A SEAT


STAY CONNECTED!

HEALTHCARE MARKETS UPDATE
NEWS & EVENTS

Learn more about the DNB//Back Bay Partnership and subscribe to our weekly market overview for healthcare IPOs, licensing, venture, M&A, follow-on, and PIPE/RDO activity.

MEET THE TEAM


Nasdaq welcomed the DNB//Back Bay Partnership with a tribute on the Nasdaq Tower, May 2023, New York City.

  • DNB is Norway’s largest financial institution and leading corporate and investment bank, with international expertise in corporate banking and public capital markets across selected industry sectors, specializing in arranging financing for healthcare companies globally.

    DNB has been established in North America since 1975, with a full-service branch in New York that serves corporate customers in the bank’s strategic business areas. A full range of wholesale investment banking services is provided by DNB Markets, Inc., a U.S. registered broker-dealer and wholly owned subsidiary of DNB Bank ASA in New York, established in 2003. Visit DNB Bank’s healthcare pages to learn more, here.

  • Back Bay Life Science Advisors (Back Bay) provides life science strategy and investment banking guidance and execution to global life science companies and their investors. Back Bay’s integrated strategy and banking teams advise companies on all aspects of life science, healthcare technology and drug development, including planning an initial concept, product commercialization, franchise growth, licensing, partnering, M&A, divestiture and more.

    With a strong presence in Europe and the Nordic markets and a global reach, Back Bay has guided hundreds of healthcare companies through the complexities of commercial development and transactions. Every project and transaction is rooted in Back Bay’s deep expertise in life science, healthcare industry strategy and investment banking.


 
 

Matching strategic guidance, capital and transaction execution for global biopharma, medtech, healthtech and life science companies at every stage and sector


STRATEGIC ADVISORY

  • Franchise, business unit & therapeutic areas strategy

  • Healthcare and life

    science product positioning and branding

  • Corporate growth

    strategies

  • Liquidity and exit

    planning

  • Healthcare transaction guidance and strategy

  • Due diligence and

    valuation

  • Market analytics

MERGERS & ACQUISITIONS

  • Divestments

  • Licensing (buy and sell side)

  • Partnering

  • Mergers & acquisitions

  • Recapitalization

  • NewCo formation

  • Fairness opinion

FIXED INCOME ORIGINATION

  • Investment Grade Bonds

  • High yield bonds

  • Convertible bonds

  • US private placements

  • Debt and restructuring

    advisory

EQUITY CAPITAL MARKETS

  • Franchise, business unit & therapeutic areas strategy

  • Healthcare and life science product positioning and branding

  • Corporate growth strategies

  • Liquidity and exit planning

  • Healthcare transaction guidance and strategy

  • Due diligence and valuation

  • Market analytics

ACQUISITION FINANCING
& LOAN ORIGINATION

  • Underwriting of acquisition debt

  • Bridge facilities

  • Revolving credit facilities

  • Commercial term loan

  • Institutional term loan

  • IPO financing

  • Debt advisory

TREASURY SOLUTIONS

  • Foreign exchange

  • Interest rate derivatives

  • Letters of credit & bank guarantees

  • Cash management

  • Working capital & trade finance

  • Electronic banking

  • Liquidity management

  • Check receivables and

    payables

  • ACH, wires and global payments

Disclosures

This presentation is strictly confidential and prepared exclusively for the benefit and internal use of the client to whom it is directly addressed and delivered (including such client’s subsidiaries, the “Company”) and not for distribution or publication.

The information may not be reproduced without the consent of Back Bay Life Science Advisors LLC (“Back Bay”) and DNB Markets, Inc. (“DNB”).

The information in this presentation is based upon management forecasts supplied by the Company and publicly available information. Back Bay and DNB have each relied upon and assumed, without independent verification, the accuracy and completeness of all information available. Opinions and estimates constitute judgment and should be regarded as indicative, preliminary and for illustrative purposes only. Statements in the presentation reflect prevailing conditions and the opinions of Back Bay and DNB, respectively, at the date the presentation was prepared, all of which are accordingly subject to change.  Neither Back Bay nor DNB warrant that the information in the presentation is exact, correct or complete. The presentation is for discussion purposes only and is incomplete without reference to, and should be viewed solely in conjunction with, oral briefings provided by Back Bay and DNB.

Analyses are not and do not purport to be appraisals of the assets, shares, or business of the Company or any other entity. Back Bay and DNB make no representation as to the actual value which may be received in connection with a transaction nor the legal, tax or accounting effects of consummating a transaction. Unless expressly contemplated hereby, the information in this presentation does not take into account the effects of a possible transaction or transactions involving an actual or potential change of control, which may have significant valuation and other effects.

This presentation is not an offer or a recommendation to purchase or sell financial instruments or assets and does not constitute a commitment by either Back Bay or DNB to underwrite, subscribe for or place any securities or to extend or arrange credit to or to provide any other services. Back Bay and DNB do not accept any responsibility for direct or indirect losses that are due to the interpretation, and/or use, of this presentation.

Rules regarding confidentiality and other internal guidelines limit the exchange of information between different units of Back Bay, DNB and their respective affiliates. Employees in DNB who have prepared this presentation may be prevented from using, or being aware of, information in other units or entities in the DNB Group which may be relevant to this presentation.

About DNB and Back Bay:

DNB Markets, Inc. is a U.S. registered broker-dealer and a separately incorporated subsidiary of DNB Bank ASA in Norway. DNB Markets, Inc. is a member of the Financial Industry Regulatory Authority (“FINRA”) and the Securities Investor Protection Corporation (“SIPC”). Securities products and services are offered in the U.S. through DNB Markets, Inc.

DNB Markets, is a division of DNB Bank ASA in Norway. Securities products and services are offered in the European Economic Area though DNB Markets.

Back Bay Life Science Advisory LLC is a wholly owned subsidiary of Back Bay Life Science Advisors, LLC.

About the DNB and Back Bay Partnership:

The DNB-Back Bay Partnership was created to drive global healthcare growth and innovation. The DNB-Back-Bay Partnership provides a full range of strategic advisory and financing capabilities along the full continuum of life science and healthcare company development.  The DNB-Back Bay Partnership, is a marketing term referring to a strategic agreement between DNB Markets, Inc. and Back Bay Life Science Advisors. More information about the DNB-Back Bay Partnership can be found here: https://www.dnb.no/en/business/industry-expertise/healthcare/dnb-back-bay